Royalty Pharma stock

RPRX · NASDAQ · USD

Compare Royalty Pharma
$68.83Change from previous close: −0.69%Absolute change: −$0.48

Close · November 16, 2026

Price history

+75.77% over the period

1 year: from $39.16 (November 17, 2025) to $68.83 (November 16, 2026), +75.77%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$68.83
October 30, 2026$67.18
September 30, 2026$58.36
August 31, 2026$61.41
July 31, 2026$58.43
June 30, 2026$56.07
May 29, 2026$55.76
April 30, 2026$50.09
March 31, 2026$47.97
February 27, 2026$46.21
January 30, 2026$41.68
December 31, 2025$38.64
November 28, 2025$40.02
November 17, 2025$39.16

At a glance

  • The company

    Buyer of biopharmaceutical royalties and funder of innovation in the biopharmaceutical industry

  • Latest results

    Quarter to September 30, 2026 · EPS $1.21 (estimate $1.18)

TickerLandia's take on Royalty Pharma

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$37.31
52-wk high$70.37

−2.19% from the 52-week high

Analysts · 9 analysts

Average target$72.00+4.61% vs. price

Buy 7 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: Royalty Pharma

Compared with similar companies: very strong momentum, very low financial strength, and very low risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Royalty Pharma is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Royalty Pharma's P/E today is 38.6, above the median of its last 5 fiscal years (21.7; between 11.1 and 37.9 from 2020 to 2025). Royalty Pharma's P/E (trailing 12 months): 45.3, +15% against the median of a group of 6 similar companies (39.3).

P/E compared with its history

Compared with 6 similar companies

Royalty Pharma's metrics compared with similar companies
MetricRoyalty PharmaPosition in the groupBand
P/E (trailing 12 months)45.3Middle
Forward P/E11.7Low
Operating margin64.4%High
ROE12.1%Middle
Debt/equity0.88High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Royalty Pharma. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$674.14M

Latest quarter · Q2 2026

Net income

$17.88M

Latest quarter · Q2 2026

Quarterly net margin

2.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$39.85B
P/E
45.3
EPS
$1.53
Volume
2.95M
Daily trading
€204.78M
Dividend yield
1.37%
Last ex-dividend on November 13, 2026

How Royalty Pharma is changing

All results
  • Revenue grew 2.3% a year on average over the last 5 years

  • Operating margin rose from 41.3% to 65.6%

  • Shares outstanding up 50.3% in 5 years

Returns

Royalty Pharma returns with dividends

$1,000 invested in Royalty Pharma 5 years ago, on November 16, 2021, would be worth $1,848 today with dividends reinvested: +84.79% in total, +13.07% per year. On price alone it would be $1,639 (+63.92%).

PeriodRoyalty PharmaS&P 500$1,000 becomes
1 month+12.91%−3.12%$1,129
6 months+30.24%+2.07%$1,302
Year to date+78.13%+10.46%$1,781
1 year+78.78%+13.33%$1,788
3 years+178.80%+67.73%$2,788
5 years+84.79%+60.86%$1,848

Over the last 6 months it has done better than 66% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Royalty Pharma: technical analysis

Royalty Pharma is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.7% below its all-time closing high ($70.01, November 11, 2026).

Trend
Upward
RSI (14 sessions)
69
Between 30 and 70
vs 200-session average
+25.69%

Support and resistance

Price areas where Royalty Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$68.83
  3. Support$56.31−18.19%3 touches, last on August 4, 2026
  4. Support$55.04−20.03%2 touches, last on October 8, 2026
  5. Support$49.09−28.69%2 touches, last on May 4, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.24
Volatility (60 sessions, annualised)
23.7%
Largest fall in the last year
−12.12%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Royalty Pharma: seasonality

Average monthly price change over 7 years

+4.4%Jan+2.2%Feb−1.7%Mar+1.5%Apr−1.4%May+0.8%Jun+0.1%Jul−0.8%Aug−3.9%Sep+2.6%Oct+4.4%Nov+0.6%Dec

Over the last 7 years, the strongest month for Royalty Pharma has been November: +4.45% on average, positive in 5 years out of 6. The weakest has been September: −3.88% on average, positive in 1 years out of 7.

Show chart data
MonthAverageMedianPositive years
January+4.37%+0.73%4 of 6
February+2.15%+2.79%3 of 6
March−1.69%−0.33%3 of 6
April+1.46%+2.65%4 of 6
May−1.43%−2.21%2 of 6
June+0.76%+1.36%4 of 6
July+0.08%+2.14%5 of 7
August−0.80%−2.23%3 of 7
September−3.88%−3.90%1 of 7
October+2.56%+5.33%4 of 7
November+4.45%+2.32%5 of 6
December+0.60%−1.62%3 of 6

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Royalty Pharma and its competitors

Royalty Pharma plc is known by its royalty portfolio on medicines, which covers about 35 marketed therapies and around 20 development-stage product candidates. The company buys biopharmaceutical royalties and funds innovation in the biopharmaceutical industry, with a portfolio spanning rare disease, oncology, neuroscience, infectious disease, hematology and diabetes. It also has a research and development funding collaboration to advance JNJ-4804, an investigational medicine for autoimmune diseases.

Headquarters
New York, United States
Employees
100
Founded
1996
Chief executive
Pablo Legorreta
Royalty Pharma and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Royalty PharmaRPRX$39.85B64.4%45.3+30.24%
Revolution MedicinesRVMD$37.27B-853.0%—+15.07%
BeOne MedicinesONC$47.58B17.8%53.4+41.17%
Roivant SciencesROIV$28.64B-3,226.3%—+33.87%
InsmedINSM$26.58B-41.7%—+13.65%
argenxARGX$60.37B31.9%33.3+20.40%

Same industry or related industries, similar size. Compare Royalty Pharma with its competitors · Full profile